Bristol Myers' blood cancer cell therapy succeeds in mid-stage trial
BioNTech and Bristol Myers Squibb Announce Global Strategic Partnership to Co-Develop and Co-Commercialize Next-generation Bispecific Antibody Candidate BNT327 Broadly for Multiple Solid Tumor Types
Bristol Myers Wins FDA Approval of CAR-T for Some Blood Cancers